Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 10, 2003. The report serves as a notification of changes in director interests rather than a comprehensive financial results announcement.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. No financial performance data is included in this specific report.
Material Changes
The only material change disclosed is an increase in the shareholding of Dr. J.P. Garnier. On July 10, 2003, his interest in Ordinary Share ADRs increased by 1,081.737 shares. This increase resulted from the reinvestment of dividends paid on July 3, 2003, at a price of $40.925 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. The document is strictly limited to reporting the director's transaction.
Key Facts for Investor Verification
- Director Dr. J.P. Garnier increased his ADR holdings by 1,081.737 shares.
- The transaction price was $40.925 per ADR.
- The increase was driven by dividend reinvestment from the July 3, 2003 payment.
- No financial performance metrics are disclosed in this filing.